Tort Attorneys Concerned By State Claim Pre-emption Described In OTC Rule
This article was originally published in The Tan Sheet
An FDA proposed rule has a lawyer's group concerned the agency is moving toward a policy of pre-empting state tort law regarding liability claims linked to over-the-counter products
You may also be interested in...
McNeil Consumer Healthcare argues in a consumer injury lawsuit that the Supreme Court's 2009 decision in Wyeth v. Levine does not apply to nonprescription pharmaceuticals because OTC and Rx drugs are covered by different regulatory labeling schemes.
This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation
Citing a crisis within FDA, members of Congress are demanding that the agency withdraw its proposed rule to limit when drug and device manufacturers can revise their product labeling without prior FDA approval